Answers are grounded in this paper and cite their sources.
In mass-spectrometry–based proteomics, a substantial proportion of acquired spectra remain unidentified, concealing a vast reservoir of biological variations commonly termed the "dark proteome", potentially obscuring sequence mutations, non–canonical peptides and post–translational modifications. Existing deep-learning methods largely rely on supervised training with peptide–spectrum matches (PSMs), limiting their ability to learn from the much larger pool of unannotated spectra. Here we introduce π–SPECFormer, a mass–spectrometry foundation model pre-trained on 291 million spectra through a two-stage framework that combines self-supervised and PSMs–guided representation learning. π–SPECFormer transfers effectively to de novo peptide sequencing, spectrum clustering and modification detection, consistently outperforming task-specific baselines. When applied to proteomic profiles from 103 individuals with lung adenocarcinoma, the model identified nine high-confidence mutated peptides, including six that were absent from the reference databases. π–SPECFormer thus enables unbiased decoding of molecular complexity beyond the boundaries of the canonical proteome.
No takes yet. Share an insight, caveat, or question.
Ling et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: